Publications dans lesquelles il/elle collabore avec Esteban Daudén Tello (79)

2024

  1. Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting

    International Journal of Dermatology, Vol. 63, Núm. 4, pp. 503-511

  2. Psoriasis Severity, Health-Related Quality of Life, Work Productivity, and Activity Impairments Among Patients With Moderate to Severe Psoriasis Receiving Systemic Treatment: Real-World Data From Clinical Practice in Spain

    Actas Dermo-Sifiliograficas, Vol. 115, Núm. 1, pp. 1-9

  3. Ustekinumab is effective and safe in the long-term treatment of erythrodermic psoriasis: Multicenter study in daily practice

    JEADV Clinical Practice

2023

  1. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

    Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 12, pp. 2517-2525

  2. Effectiveness of secukinumab for the treatment of erythrodermic psoriasis: Multicentre study in daily practice

    Journal of the European Academy of Dermatology and Venereology

  3. Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1)

    Dermatology and Therapy, Vol. 13, Núm. 1, pp. 329-345

  4. Generalized Pustular Psoriasis: A Review on Clinical Characteristics, Diagnosis, and Treatment

    Dermatology and Therapy, Vol. 13, Núm. 3, pp. 673-688

  5. High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting

    International Journal of Dermatology

  6. Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice

    Journal of the European Academy of Dermatology and Venereology

  7. The DERMACLEAR study: Verification results of a natural language processing system in dermatology

    JEADV Clinical Practice, Vol. 2, Núm. 4, pp. 775-785

2022

  1. Differences in epidemiology, comorbidities and treatment choice between plaque psoriasis and pustular psoriasis: results from the BIOBADADERM registry

    British Journal of Dermatology

  2. Effectiveness and safety profile of secukinumab for the treatment of patients with generalized pustular psoriasis in daily practice

    Journal of the European Academy of Dermatology and Venereology

  3. Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting

    Dermatologic Therapy, Vol. 35, Núm. 8

  4. Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience

    Actas Dermo-Sifiliograficas, Vol. 113, Núm. 4, pp. 401-406

  5. Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients

    Dermatologic Therapy, Vol. 35, Núm. 12

  6. The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry

    Journal of Dermatological Treatment, Vol. 33, Núm. 4, pp. 2110-2117

  7. Ustekinumab to guselkumab transitions: A series of 54 patients emulating the navigate trial in real life

    Dermatologic Therapy, Vol. 35, Núm. 10

2021

  1. A novel circulating microRNA for the detection of acute myocarditis

    New England Journal of Medicine, Vol. 384, Núm. 21, pp. 2014-2027

  2. Effect of Sex in Systemic Psoriasis Therapy: Differences in Prescription, Effectiveness and Safety in the BIOBADADERM Prospective Cohort

    Acta dermato-venereologica, Vol. 101, Núm. 1, pp. adv00354

  3. Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study

    Journal of Allergy and Clinical Immunology, Vol. 147, Núm. 1, pp. 60-71